• Addex Therapeutics published its annual report for 2025, highlighting progress in chronic cough and brain injury recovery programs.
• Indivior completed IND-enabling studies for selected GABAB PAM candidate in substance use disorder under existing partnership.
• Addex reported its independently selected GABAB PAM candidate showed robust anti-tussive effects across several preclinical models for chronic cough.
• Company signed option and collaboration agreement with Sinntaxis on April 30, 2025 to secure exclusive IP license covering use of mGlu5 inhibitors in brain injury recovery.
• Addex regained full development and commercialization rights to Phase 2 mGlu2 PAM asset ADX71149 from Johnson and Johnson.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.